2024-02-21 08:36:08 ET
Summary
- EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care.
- The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business.
- EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing.
EyePoint ( EYPT ) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901....
Read the full article on Seeking Alpha
For further details see:
EyePoint Is Betting The Bank On EYP-1901